Startup Valuations, Biotech’s Crunch & AI’s Massive TAM | E2147

Key Concepts

• AI investment landscape: Early-stage rounds, founder quality, market opportunity, ambition.
• Biotech market depression: Public market closure, private market impact, fundraising difficulties.
• Venture capital paradox: High prices vs. low prices, expected returns, substantive breakthroughs.
• AI's impact on labor markets: Short-term dislocations, technology revolution, labor market impact.
• Product market fit: Strong product market fit, enterprise adoption, net revenue retention.
• AI foundation models: Application layer, competition, market space, startup innovation.
• AI in healthcare: Virtual modeling, drug development, patient care, AI doctor.
• Founding teams: Solo founders, team size, venture capital willingness, team dynamics.
• Hiring trends: Rapid headcount growth, AI native products, burn dynamics, go-to-market strategy.
• Exit strategies: M&A, IPO, returns context, LP sentiment, market outlook.
• Fertility space: Fertility treatments, global birth rates, in vitro fertilization, automation.

Deals and Deal Making in Q2

• Overall deal velocity slowed down, but total capital invested in earlier stages went up.
• Estasia Myers (Felicis): Founder quality is increasing, leading to larger early-stage rounds. The AI explosion is democratizing access to tools, enabling faster building and higher ARR. Flight to quality companies targeting $100 billion markets.
• Matt Turk (First Mark): Difficult to find attractive entry prices. AI investments at Series A are routinely at nine-figure pre-money valuations. Hyper-competitive market.
• DA Wall (Time Bio Ventures): Biotech is in a "Great Depression" due to a shut-down capital market, led by closed public markets. Difficult for companies to find capital, even those with an AI theme.

Biotech Market Dynamics

• Biotech companies traditionally go public earlier to access capital for clinical trials.
• The public market is driven by biotech specialist hedge funds and large multistrategy hedge funds.
• Generalist investors rotated out of biotech, leaving only specialist funds, which are not large enough to carry all companies.
• Competition with large-cap tech for public risk capital has led to a shortage of capital for biotech companies.

Cash Efficiency and Startup Strategy

• Stephen Estus (CLA): Companies don't need to raise as much as in the past. Founders must carefully forecast and model their capital needs.
• High prices in some sectors may foretell low expected returns, while low prices in biotech may foretell high expected returns.
• Substantive breakthroughs like AI make it hard to tell if high prices are warranted.

AI Market Opportunities and Concerns

• AI shift is different because it can target labor budgets, a $35 trillion market.
• AI software products and infrastructure could increase the S&P 500's net margins by 5%, leading to $600 billion in profits and $1 trillion in new market value.
• Microsoft layoffs highlight potential short-term dislocations in the labor markets.

Portfolio Performance in Q2

• DA Wall (Time Bio Ventures): Operationally, most companies are doing well, benefiting from early funding rounds. Companies dependent on risk capital are having a hard time.
• Matt Turk (First Mark): All companies are "crushing it."
• Estasia Myers (Felicis): Companies in generative AI are experiencing incredible tailwinds. Buyers are trying, buying, and deploying products at scale. Companies supporting the AI wave are also seeing incredible growth.

Product Market Fit and Enterprise Adoption

• Companies with strong product market fit are seeing impressive net revenue retention (NDR) numbers.
• Synthesia is in 70% of Fortune 100 companies, demonstrating rapid enterprise adoption.
• Enterprise buyers are willing and excited to bring in innovation quickly.

AI Foundation Models and Competition

• Competition from foundation AI model companies is a risk, but it also validates the space and provides acquisition opportunities.
• Agile, smart, aggressive early-stage teams have a shot at winning these markets.
• Building vertical industry-specific applications requires a lot of work, workflows, and integrations, leaving room for startups.

OpenAI Valuation

• OpenAI's multi-product approach (infrastructure, developer tools, AI applications) suggests huge upside potential.
• The multiple of current revenue growth rate versus valuation is not that crazy.
• There are risks associated with investing billions in a nonprofit company with management and developer concerns.

AI Gross Margins and Compute Costs

• The cost of inference is dropping, but many AI startups have gross margins around 50%, not 80% like SaaS companies.
• The industry is betting that the cost of inference will continue to drop.
• Some companies have negative gross margins, similar to the pre-IPO Uber phase.

Bring Your Own Cloud Model

• An interesting deployment mechanism is the "bring your own cloud" model, where infrastructure runs in the customer's environment (VPC).
• This model can lead to strong gross margins (85%+) and gives sellers more leverage against fully hosted providers.

AI in Healthcare and Voice Applications

• AI can improve client and patient care, decrease administrative overhead, and help with insurance claims.
• Voice applications can help physicians focus on patients instead of data entry.

Founding Team Dynamics

• The VC market is becoming more willing to back solo founders in the AI era.
• Solo founders can get lonely quickly, and teams of two to three founders tend to be happier.
• Teams with five founders are less common and can lead to ownership issues.

Hiring Trends and Startup Economics

• There's less appetite for rapidly growing headcount.
• AI native products empower founders to get more leverage out of engineers and handle BDR, sales, marketing, and customer success without large teams.
• Lower burn numbers give companies more runway and flexibility to spend on go-to-market activities.

Outsourcing and the Chinese Biotech Scene

• There's a trend towards outsourcing more and building valuable companies with relatively few full-time staff.
• Chinese biotech companies are leveraging CROs (outsourced service providers) to accelerate drug development.
• Global pharmaceutical companies are indifferent to geography and are willing to acquire new drugs from anywhere.

State-Level Investment and Innovation

• There's a debate about whether the US government should be pulling back from the biotech industry.
• Societies must ask what the pro and con of prioritizing innovation on their soil is.
• France is obsessed with startups, and every kid coming out of a top elite school wants to do a startup.

Academia and Entrepreneurship

• There's a hunger from students to learn more about tech and venture.
• Felicis launched a fellows program to bring bright AI students together and expose them to entrepreneurship.
• Students are encouraged to build, release, and learn from their experiences.

Exit Market and M&A

• Q2 was encouraging, with potential for both traditional exit channels (IPO) and the opening of M&A markets.
• Checkbooks seem to be opening.
• Smaller acquisitions are resuming, which is healthy for portfolios.

Fertility Space and Technology

• The global birth rate issue is about both the ability to reproduce and the interest/willingness to do so.
• Billion to One is enabling expecting families to find out whether the fetus has any congenital diseases.
• Conceivable is automating in vitro fertilization (IVF) with robotics, improving consistency and reducing costs.
• There's an opportunity to democratize access to IVF and make it accessible to every family that wants it.

Conclusion

The discussion paints a complex picture of the venture capital landscape in Q2, with AI driving significant investment and innovation in some sectors while others, like biotech, face considerable challenges. The panelists highlighted the importance of founder quality, strategic capital allocation, and adapting to evolving market dynamics. While concerns about high valuations and potential labor market disruptions exist, the overall outlook remains optimistic, with opportunities for growth and innovation across various industries.